ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine lines, wrinkles and elasticity after a single dose with the ATR-COSF cosmetic product candidate Continued improvement seen up to 48 hours First-in-human study with ATR-COSF initial results anticipated by year end Further details to be presented in a live presentation at BIO-Europe® BRANFORD, Conn. , Oct. 26, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Cofounder and Chief Operating Officer, Travis Whitfill , PhD, MPH, will present progress for its cosmetic ATR-COSF program targeting the appearance of fine lines and wrinkles. The detailed data will be presented in person at the BIO-Europe® conference in Cologne, Germany on November 10 th, 2026, at 4:45 pm CET . The ATR-COSF program uses the supernatant from a strain of S. epidermidis engineered to secrete a functional unit of the human filaggrin protein and is formulated in a hydrogel. The cosmetic product candidate was evaluated in two different models of ex vivo cosmetic surgery skin, which was maintained in serum free, nutrient-rich media. Model 1: Dorsal Skin The first model utilized dorsal torsoplasty skin explants received ~18 hours after surgery. ATR-COSF at 2% concentration in a hydrogel was topically applied to the skin samples. In addition, a hydrogel vehicle without the cosmetic supernatant ingredient was used as a control. Surface evaluation of wrinkles ("SEw") and elasticity were measured at the following time points: pre-application and post-application at T=3 hours, T=4.5 hours, T=24 hours, and T=48 hours. SEw analysis revealed that human skin topically treated with one dose of ATR-COSF showed consequential reductions in the appearance of fine lines and wrinkles of approximately 15% at 3 hours, which further improved to approximately 20% at 24 hours and showed an overall reduction of approximately 50% at 48 hours. In contrast, a single dose of the hydrogel vehicle alone did not improve the appearance of fine lines and wrinkles. Instead, the appearance of fine lines and wrinkles increased by approximately 15% at the 3-hour time point and further increased to approximately 20% by 48 hours. ATR-COSF also preserved net skin elasticity over the 48-hour period, whereas the hydrogel vehicle alone was associated with a meaningful decline in elasticity. Model 2: Face Lift The second model utilized face lift skin explants received ~48 hours after surgery. ATR-COSF at concentrations of 2% and 4%, along with the hydrogel vehicle-only control, were topically applied as a single dose. Skin elasticity was measured 6 hours post-application. The following parameters of elasticity were measured after application of a single dose: R0: Maximum deformation under suction; indicates tissue distensibility R2: Overall elasticity, including the skin's ability to recover after suction R5: Net elasticity; useful for comparing elastic behavior between samples R7: Proportion of immediate elastic recovery R8: Total recovery At the 6-hour time point, the 4% ATR-COSF formulation outperformed the 2% formulation and the hydrogel alone in each of the above elasticity measures. Both the 2% ATR-COSF formulation and hydrogel alone showed either a decline in elasticity or no improvement, whereas the ATR-COSF 4% formulation demonstrated clear improvements across the measured elasticity parameters. A first-in-human clinical study of 4% ATR-COSF is anticipated in approximately 30 subjects with initial data expected by year end. "Our latest ex vivo results bridge the gap between our scientific labs and real life. By successfully delivering filaggrin domains into human skin and for the first time demonstrating improvements on the appearance of fine lines and wrinkles, we are opening a new frontier in anti-aging cosmetic science. We look forward to presenting our ATR-COSF results in more detail during BIO- EUROPE ," said Francisco Salva , CEO of Azitra . He continued, "We remain appropriately funded to remain on track to reach our next goal of releasing initial data from our clinical, human anti-wrinkle study by year end, a key milestone for our fundamental, institutional investors who supported us earlier this year. Once the data is released, they have a near term opportunity to invest another $5.25 million to $10.5 million from financial instruments issued in that transaction." In addition to presenting the progress of the ATR-COSF program, Dr. Whitfill will also conduct one-on-one meetings with potential partners and investors during the conference. About Azitra, Inc. Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision d